As such IL-17 signaling may be a target for microbiota-directed interventions in EED, but neutralization of IL-17 with monoclonal antibodies in inflammatory bowel disease paradoxically exacerbated symptoms [61]. This evidence concerns the gene IL17A and inflammatory bowel disease.